Literature DB >> 24997998

Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Vineet Sangar1, Cory C Funk1, Ulrike Kusebauch1, David S Campbell1, Robert L Moritz1, Nathan D Price2.   

Abstract

Glioblastoma multiforme is a highly invasive and aggressive brain tumor with an invariably poor prognosis. The overexpression of epidermal growth factor receptor (EGFR) is a primary influencer of invasion and proliferation in tumor cells and the constitutively active EGFRvIII mutant, found in 30-65% of Glioblastoma multiforme, confers more aggressive invasion. To better understand how EGFR contributes to tumor aggressiveness, we investigated the effect of EGFR on the secreted levels of 65 rationally selected proteins involved in invasion. We employed selected reaction monitoring targeted mass spectrometry using stable isotope labeled internal peptide standards to quantity proteins in the secretome from five GBM (U87) isogenic cell lines in which EGFR, EGFRvIII, and/or PTEN were expressed. Our results show that cell lines with EGFR overexpression and constitutive EGFRvIII expression differ remarkably in the expression profiles for both secreted and intracellular signaling proteins, and alterations in EGFR signaling result in reproducible changes in concentrations of secreted proteins. Furthermore, the EGFRvIII-expressing mutant cell line secretes the majority of the selected invasion-promoting proteins at higher levels than other cell lines tested. Additionally, the intracellular and extracellular protein measurements indicate elevated oxidative stress in the EGFRvIII-expressing cell line. In conclusion, the results of our study demonstrate that EGFR signaling has a significant effect on the levels of secreted invasion-promoting proteins, likely contributing to the aggressiveness of Glioblastoma multiforme. Further characterization of these proteins may provide candidates for new therapeutic strategies and targets as well as biomarkers for this aggressive disease.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24997998      PMCID: PMC4188991          DOI: 10.1074/mcp.M114.040428

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  111 in total

1.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.

Authors:  Kathryn M Ferguson; Mitchell B Berger; Jeannine M Mendrola; Hyun Soo Cho; Daniel J Leahy; Mark A Lemmon
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

2.  Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model.

Authors:  Hao Ding; Patrick Shannon; Nelson Lau; Xiaoli Wu; Luba Roncari; Rebecca L Baldwin; Hirohide Takebayashi; Andras Nagy; David H Gutmann; Abhijit Guha
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

3.  Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.

Authors:  Mirko H H Schmidt; Frank B Furnari; Webster K Cavenee; Oliver Bögler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-06       Impact factor: 11.205

Review 4.  Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review).

Authors:  Stephen B Hunter; Daniel J Brat; Jeffrey J Olson; Andreas Von Deimling; Wei Zhou; Erwin G Van Meir
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

5.  Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.

Authors:  Huang Shao; Haiyun Y Cheng; Richard G Cook; David J Tweardy
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 7.  Oncogenic EGFR signaling networks in glioma.

Authors:  Paul H Huang; Alexander M Xu; Forest M White
Journal:  Sci Signal       Date:  2009-09-08       Impact factor: 8.192

8.  Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression.

Authors:  Keiichiro Tanaka; Noriko Hiraiwa; Hisashi Hashimoto; Yoji Yamazaki; Moriaki Kusakabe
Journal:  Int J Cancer       Date:  2004-01-01       Impact factor: 7.396

9.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.

Authors:  Monica Autiero; Johannes Waltenberger; Didier Communi; Andrea Kranz; Lieve Moons; Diether Lambrechts; Jens Kroll; Stephane Plaisance; Maria De Mol; Françoise Bono; Stefanie Kliche; Guido Fellbrich; Kurt Ballmer-Hofer; Domenico Maglione; Ulrike Mayr-Beyrle; Mieke Dewerchin; Saskia Dombrowski; Danica Stanimirovic; Paul Van Hummelen; Christoph Dehio; Daniel J Hicklin; Graziella Persico; Jean-Marc Herbert; David Communi; Masabumi Shibuya; Désiré Collen; Edward M Conway; Peter Carmeliet
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Authors:  Juxiang Cao; Jennifer Schulte; Alexander Knight; Nicholas R Leslie; Agnieszka Zagozdzon; Roderick Bronson; Yefim Manevich; Craig Beeson; Carola A Neumann
Journal:  EMBO J       Date:  2009-04-16       Impact factor: 11.598

View more
  19 in total

Review 1.  Advances in targeted proteomics and applications to biomedical research.

Authors:  Tujin Shi; Ehwang Song; Song Nie; Karin D Rodland; Tao Liu; Wei-Jun Qian; Richard D Smith
Journal:  Proteomics       Date:  2016-08       Impact factor: 3.984

2.  Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain metastasis from a papillary thyroid carcinoma.

Authors:  Hans-Juergen Schulten; Deema Hussein; Fatima Al-Adwani; Sajjad Karim; Jaudah Al-Maghrabi; Mona Al-Sharif; Awatif Jamal; Sherin Bakhashab; Jolanta Weaver; Fahad Al-Ghamdi; Saleh S Baeesa; Mohammed Bangash; Adeel Chaudhary; Mohammed Al-Qahtani
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

Review 3.  Emerging Proteomic Technologies Provide Enormous and Underutilized Potential for Brain Cancer Research.

Authors:  Qiang Tian; Vineet Sangar; Nathan D Price
Journal:  Mol Cell Proteomics       Date:  2015-09-25       Impact factor: 5.911

Review 4.  Application of targeted mass spectrometry in bottom-up proteomics for systems biology research.

Authors:  Nathan P Manes; Aleksandra Nita-Lazar
Journal:  J Proteomics       Date:  2018-02-13       Impact factor: 4.044

5.  The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells.

Authors:  Dongsic Choi; Laura Montermini; Dae-Kyum Kim; Brian Meehan; Frederick P Roth; Janusz Rak
Journal:  Mol Cell Proteomics       Date:  2018-07-13       Impact factor: 5.911

6.  Differential proteomics analysis of low- and high-grade of astrocytoma using iTRAQ quantification.

Authors:  Tong Ren; Shide Lin; Zhongfeng Wang; Aijia Shang
Journal:  Onco Targets Ther       Date:  2016-09-27       Impact factor: 4.147

Review 7.  Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker.

Authors:  Florentina Serban; Stefan-Alexandru Artene; Ada Maria Georgescu; Stefana Oana Purcaru; Daniela Elise Tache; Oana Alexandru; Anica Dricu
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

8.  Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme.

Authors:  Igor S Bryukhovetskiy; Inessa V Dyuizen; Valeriy E Shevchenko; Andrey S Bryukhovetskiy; Polina V Mischenko; Elena V Milkina; Yuri S Khotimchenko
Journal:  Mol Med Rep       Date:  2016-10-13       Impact factor: 2.952

9.  Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).

Authors:  Kevin Demeure; Fred Fack; Elodie Duriez; Katja Tiemann; Amandine Bernard; Anna Golebiewska; Sébastien Bougnaud; Rolf Bjerkvig; Bruno Domon; Simone P Niclou
Journal:  Mol Cell Proteomics       Date:  2015-08-04       Impact factor: 5.911

10.  Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma.

Authors:  Jiaze Tang; Ning Huang; Xiang Zhang; Tao Zhou; Ying Tan; Jiangli Pi; Li Pi; Si Cheng; Huzhi Zheng; Yuan Cheng
Journal:  Int J Nanomedicine       Date:  2017-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.